首页> 美国卫生研究院文献>Neuro-Oncology >RAPID IDH1 GENE MUTATION ANALYSIS FOR INTRAOPERATIVE PATHOLOGICAL DIAGNOSIS
【2h】

RAPID IDH1 GENE MUTATION ANALYSIS FOR INTRAOPERATIVE PATHOLOGICAL DIAGNOSIS

机译:快速IDH1基因突变分析用于术中病理诊断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: (blind field). METHODS: DNA extracted in 15 min from glioma tissue collected during surgery was used to test for R132 point mutations of the IDH1 gene by using real-time PCR/high resolution melting analysis method (LightCycler 480 system). Normally, detecting IDH1 mutations requires about 80 min from the start of the PCR cycle. For rapid diagnosis, however, DNA extension and annealing times in the PCR cycle were reduced by half. Our results were compared with those obtained using the regular method. RESULTS: Regular analysis and rapid diagnosis analysis were used to detect IDH1 mutations in 6 glioma cases (diffuse astrocytoma, 2 cases; oligodendroglioma, 2 cases; anaplastic astrocytoma, 1 case; glioblastoma, 1 case). Both methods produced the same results in all cases. CONCLUSIONS: Direct DNA sequencing and immunostaining can be used to identify IDH1 mutations. However, because analyses by using the former method require several hours, it cannot be used in rapid diagnosis. The latter method could not identify all R132 mutations, because the current commercially available antibodies can only detect R132H mutant proteins. This method can detect IDH1 mutation in even 1% of tumor purity, and determine all IDH1 R132 mutation-positive gliomas during surgery in 50–60 min after the tissue is collected. Further, this method could aid in intraoperative pathological diagnoses to differentiate IDH1 mutation-positive low-malignancy gliomas from gliosis and other non-neoplastic tissues. SECONDARY CATEGORY: Clinical Neuro-Oncology.
机译:背景:(盲区)。方法:采用实时PCR /高分辨率熔解分析方法(LightCycler 480系统),在手术后15分钟内从神经胶质瘤组织中提取的DNA用于检测IDH1基因的R132点突变。通常,从PCR周期开始,检测IDH1突变大约需要80分钟。但是,为了快速诊断,PCR循环中的DNA延伸和退火时间减少了一半。我们的结果与使用常规方法获得的结果进行了比较。结果:定期分析和快速诊断分析用于检测6例神经胶质瘤IDH1突变(弥漫性星形细胞瘤2例;少突胶质细胞瘤2例;间变性星形细胞瘤1例;胶质母细胞瘤1例)。在所有情况下,两种方法均产生相同的结果。结论:直接DNA测序和免疫染色可用于鉴定IDH1突变。但是,由于使用前一种方法进行分析需要几个小时,因此无法用于快速诊断。后一种方法无法识别所有R132突变,因为当前市售的抗体只能检测R132H突变蛋白。这种方法甚至可以检测到1%的肿瘤纯度的IDH1突变,并在收集组织后的50-60分钟内确定手术期间所有IDH1 R132突变阳性的神经胶质瘤。此外,该方法可有助于术中病理诊断,以将IDH1突变阳性的低恶性神经胶质瘤与神经胶质瘤和其他非肿瘤组织区分开。第二类:临床神经肿瘤学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号